There is a paucity of data on research funding for male reproductive health. We investigated the research funding for male reproductive health and infertility by examining publicly accessible databases from the UK and US government funding agencies. Information on the funding provided to male–based and 40 female–based research was collected using public accessed web databases from the UKRI–GTR, the NIHR's Open Data Summary, and the US' NIH RePORT. Funded projects that began research activity between January 2016 to December 2019 were recorded, along with their grant and project details. Strict inclusion–exclusion criteria were followed for both UK and US data with a primary research focus on male infertility, reproductive health and disorders, and contraception development. Funding support was divided into three research groups: male–based, female–based, and not–specified research. Between the 4–year period, the UK is divided into 5 funding periods, starting from 2015/16 to 2019/20, and the US is divided into 5 fiscal years, from 2016 to 2020. Between January 2016 to December 2019, UK agencies awarded a total of 11,767,190 GBP to 18 projects for male–based research and 29,850,945 GBP to 40 projects for female–based research. There was no statistically significant difference in funding average between the two research groups. The US NIH funded 76 projects totaling 59,257,746 US dollars for male–based research and 99 projects totaling 83,272,898 US dollars for female–based research. There was no statistically significant difference in funding average between the two groups. The findings of this study cannot be used to generalize and reflect global funding trends towards infertility and reproductive health as the data collected followed a narrow funding timeframe from government agencies and only two countries. Other funding sources such as charities, industry and major philanthropic organizations were not evaluated. This is the first study examining funding granted by main government research agencies from the UK and US for male reproductive health. This study should stimulate further discussion of the challenges of tackling male infertility and reproductive health disorders and formulate appropriate investment strategies.